|
[1]
|
[1]CHANG K, PASTAN I.Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas and ovarian cancers[J].Cell Biology, 1996, 93 (2) :136-140.[1]CHANG K, PASTAN I.Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas and ovarian cancers[J].Cell Biology, 1996, 93 (2) :136-140.
|
|
[2]
|
[2]INGEGERD H, EITEN F, THORSTEN V, et al.Anti-MSLN antibodies and MSLN relate to the clinical state in ovarian carer patients[J].Cancer Epidelmiol Biomarkers Prev, 2008, 17 (6) :1520-1526.[2]INGEGERD H, EITEN F, THORSTEN V, et al.Anti-MSLN antibodies and MSLN relate to the clinical state in ovarian carer patients[J].Cancer Epidelmiol Biomarkers Prev, 2008, 17 (6) :1520-1526.
|
|
[3]
|
[3]HASSAN R, BERA T, PASTAN I.Mesothelin:a new target for immunotherapy[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2004, 10 (12 Pt 1) :3937-3942.[3]HASSAN R, BERA T, PASTAN I.Mesothelin:a new target for immunotherapy[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2004, 10 (12 Pt 1) :3937-3942.
|
|
[4]
|
[4]BERATK, PASTAN I.Mesothelin is not required for normal mouse development or reproduction[J].Mol Cell Biol, 2000, 20 (8) :2901-2906.[4]BERATK, PASTAN I.Mesothelin is not required for normal mouse development or reproduction[J].Mol Cell Biol, 2000, 20 (8) :2901-2906.
|
|
[5]
|
[5]RUMP A, MORIKAWA Y, TANAKA M, et al.Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion[J].J Biol Chem, 2004, 279 (10) :9190-9198.[5]RUMP A, MORIKAWA Y, TANAKA M, et al.Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion[J].J Biol Chem, 2004, 279 (10) :9190-9198.
|
|
[6]
|
[6]NORIHISA U, YOICHIRO M, AIROT.MSLN promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast[J].Cancer Cells Mol Cancer Res, 2008, 6 (2) :1-8.[6]NORIHISA U, YOICHIRO M, AIROT.MSLN promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast[J].Cancer Cells Mol Cancer Res, 2008, 6 (2) :1-8.
|
|
[7]
|
[7]BHARADWAJ U, MARIN-MULLER C, ZHANG Y, et al.Mesothelin overexpression promotes autocrine IL-6/s IL-6R trans-signaling to stimulate pancreatic cancer cell proliferation[J].Journal of Surgical Research, 2011, 32 (7) :1013-1024.[7]BHARADWAJ U, MARIN-MULLER C, ZHANG Y, et al.Mesothelin overexpression promotes autocrine IL-6/s IL-6R trans-signaling to stimulate pancreatic cancer cell proliferation[J].Journal of Surgical Research, 2011, 32 (7) :1013-1024.
|
|
[8]
|
[8]ORDEZ N G.Application of mesothelin immunostaining in tumor diagnosis[J].Am J Surg Pathol, 2003, 27 (11) :1418-1428.[8]ORDEZ N G.Application of mesothelin immunostaining in tumor diagnosis[J].Am J Surg Pathol, 2003, 27 (11) :1418-1428.
|
|
[9]
|
[9]ARGANI P, IACOBUZIO-DONAHUE C, RYU B, et al.Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas:identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE) [J].Clin Cancer Res, 2001, 7 (12) :3862-3868.[9]ARGANI P, IACOBUZIO-DONAHUE C, RYU B, et al.Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas:identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE) [J].Clin Cancer Res, 2001, 7 (12) :3862-3868.
|
|
[10]
|
[10]HASSAN R, KREITMAN RJ, PASTAN I, WILLINGHAM MC.Localization of mesothelin in epithelial ovarian cancer[J].Appl Immunohistochem Mol Morphol, 2005, 13 (3) :243-247.[10]HASSAN R, KREITMAN RJ, PASTAN I, WILLINGHAM MC.Localization of mesothelin in epithelial ovarian cancer[J].Appl Immunohistochem Mol Morphol, 2005, 13 (3) :243-247.
|
|
[11]
|
[11]HOLLEVOET K, BERNARD D, DE G F, et al.Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum[J].Clinical Chemistry, 2009, 55 (7) :1431-1433.[11]HOLLEVOET K, BERNARD D, DE G F, et al.Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum[J].Clinical Chemistry, 2009, 55 (7) :1431-1433.
|
|
[12]
|
[12]BOUDVILLE N, PAUL R, ROBINSON B W S, et al.Mesothelin and kidney function--analysis of relationship and implications for mesothelioma screening[J].Lung Cancer, 2011, 73 (3) :320-324.[12]BOUDVILLE N, PAUL R, ROBINSON B W S, et al.Mesothelin and kidney function--analysis of relationship and implications for mesothelioma screening[J].Lung Cancer, 2011, 73 (3) :320-324.
|
|
[13]
|
[]
|
|
[14]任玉霞, 吴京芳.卵巢癌患者血清可溶性间皮素相关蛋白的检测及其意义[J].中国实验诊断学, 2014, 18 (1) :86-89.[14]任玉霞, 吴京芳.卵巢癌患者血清可溶性间皮素相关蛋白的检测及其意义[J].中国实验诊断学, 2014, 18 (1) :86-89.
|
|
[15]毕波, 潘逸茹, 周慧敏, 等.卵巢癌患者血清和肿瘤组织CA125和SMRP表达的临床意义[J].国际检验医学杂志, 2015, 36 (1) :22-24.[15]毕波, 潘逸茹, 周慧敏, 等.卵巢癌患者血清和肿瘤组织CA125和SMRP表达的临床意义[J].国际检验医学杂志, 2015, 36 (1) :22-24.
|
|
[16]
|
[16]WU XI, LI D, LIU L, et al.Serum soluble mesothelin-related peptide (SMRP) :A potential diagnostic and monitoring marker for epithelial ovarian cancer[J].Arch Gynecol Obstet, 2014, 289 (6) :1309-1402.[16]WU XI, LI D, LIU L, et al.Serum soluble mesothelin-related peptide (SMRP) :A potential diagnostic and monitoring marker for epithelial ovarian cancer[J].Arch Gynecol Obstet, 2014, 289 (6) :1309-1402.
|
|
[17]邱振华, 王茂生, 杨长福, 等.卵巢癌患者血清糖链抗原125联合人附睾上皮分泌蛋白4及可溶性间皮素相关肽测定临床价值[J].中华实用诊断与治疗杂志, 2015, 29 (6) :583-585.[17]邱振华, 王茂生, 杨长福, 等.卵巢癌患者血清糖链抗原125联合人附睾上皮分泌蛋白4及可溶性间皮素相关肽测定临床价值[J].中华实用诊断与治疗杂志, 2015, 29 (6) :583-585.
|
|
[18]
|
[18]IBRAHIM M, BAHAA A, IBRAHIM A, et al.Evaluation of serum mesothelin in malignant and benign ovarian masses[J].Arch Gynecol Obstet, 2014, 290 (1) :107-113.[18]IBRAHIM M, BAHAA A, IBRAHIM A, et al.Evaluation of serum mesothelin in malignant and benign ovarian masses[J].Arch Gynecol Obstet, 2014, 290 (1) :107-113.
|
|
[19]
|
[19]HELLSTROM I, RAYCRAFT J, KANAN S, et al.mesothelin variant 1 is released from tumor cells as a diagnostic marker[J].Cancer Epidemiol Biomarkers Prev, 2006, 15 (5) :1014-1020.[19]HELLSTROM I, RAYCRAFT J, KANAN S, et al.mesothelin variant 1 is released from tumor cells as a diagnostic marker[J].Cancer Epidemiol Biomarkers Prev, 2006, 15 (5) :1014-1020.
|
|
[20]
|
[20]CAO D, JI H, RONNETT BM.Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary[J].International Journal of Gynecological Pathology, 2005, 24 (24) :67-72.[20]CAO D, JI H, RONNETT BM.Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary[J].International Journal of Gynecological Pathology, 2005, 24 (24) :67-72.
|
|
[21]杨光.间皮素在胰腺癌组织及周围淋巴结中的表达及临床意义[D].沈阳:中国医科大学 (硕士论文) , 2008.[21]杨光.间皮素在胰腺癌组织及周围淋巴结中的表达及临床意义[D].沈阳:中国医科大学 (硕士论文) , 2008.
|
|
[22]杜以龙.胰腺癌组织中PSCA、Mesothelin的表达及其临床意义[D].苏州:苏州大学 (硕士论文) , 2009.[22]杜以龙.胰腺癌组织中PSCA、Mesothelin的表达及其临床意义[D].苏州:苏州大学 (硕士论文) , 2009.
|
|
[23]
|
[23]JHALA N, JHALA D, VICKERS S M, et al.Biomarkers in diagnosis of pancreatic carcinoma in fine-needle aspirates[J].American Journal of Clinical Pathology, 2006, 126 (4) :572-579.[23]JHALA N, JHALA D, VICKERS S M, et al.Biomarkers in diagnosis of pancreatic carcinoma in fine-needle aspirates[J].American Journal of Clinical Pathology, 2006, 126 (4) :572-579.
|
|
[24]
|
[24]DIM DC, FENG JIANG, QI Q, et al.The usefulness of S100P, mesothelin, fascin, prostate stem cell antigen, and14-3-3 sigma in diagnosing pancreatic adenocarcinoma in cytological specimens obtained by endoscopic ultrasound guided fine-needle aspiration[J].Diagnostic Cytopathology, 2014, 42 (3) :193-199.[24]DIM DC, FENG JIANG, QI Q, et al.The usefulness of S100P, mesothelin, fascin, prostate stem cell antigen, and14-3-3 sigma in diagnosing pancreatic adenocarcinoma in cytological specimens obtained by endoscopic ultrasound guided fine-needle aspiration[J].Diagnostic Cytopathology, 2014, 42 (3) :193-199.
|
|
[25]
|
[25]ROBINSON BW, CREANEY J, LAKE R, et al.Mesothelin-family proteins and diagnosis of mesothelioma[J].Lancet, 2003, 362 (9396) :1612-1616.[25]ROBINSON BW, CREANEY J, LAKE R, et al.Mesothelin-family proteins and diagnosis of mesothelioma[J].Lancet, 2003, 362 (9396) :1612-1616.
|
|
[26]
|
[26]HOLLEVOET K, NACKAERTS K, GOSSELIN R, et al.Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma[J].Journal of Thoracic Oncology Official Publication of the International Association for the Study of Lung Cancer, 2011, 6 (11) :1930-1937.[26]HOLLEVOET K, NACKAERTS K, GOSSELIN R, et al.Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma[J].Journal of Thoracic Oncology Official Publication of the International Association for the Study of Lung Cancer, 2011, 6 (11) :1930-1937.
|
|
[27]
|
[27]BLANQUART C, GUEUGNON F, NGUYEN J M, et al.CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions[J].Journal of Thoracic Oncology Official Publication of the International Association for the Study of Lung Cancer, 2012, 7 (7) :883-889.[27]BLANQUART C, GUEUGNON F, NGUYEN J M, et al.CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions[J].Journal of Thoracic Oncology Official Publication of the International Association for the Study of Lung Cancer, 2012, 7 (7) :883-889.
|
|
[28]
|
[28]HOOPER CE, MORLEY AJ, VIRGO P, et al.A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions[J].European Respiratory Journal, 2013, 41 (1) :18-24.[28]HOOPER CE, MORLEY AJ, VIRGO P, et al.A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions[J].European Respiratory Journal, 2013, 41 (1) :18-24.
|
|
[29]
|
[29]CREANEY J, DICK I M, DARE H, et al.Does CA125binding to mesothelin impact the detection of malignant mesothelioma[J].Lung Cancer, 2013, 80 (1) :39-44.[29]CREANEY J, DICK I M, DARE H, et al.Does CA125binding to mesothelin impact the detection of malignant mesothelioma[J].Lung Cancer, 2013, 80 (1) :39-44.
|
|
[30]
|
[30]FILIBERTI R, PARODI S, LIBENER R, et al.Diagnostic value of mesothelin in pleural fluids:comparison with CYFRA 21-1 and CEA[J].Medical Oncology, 2013, 30 (2) :1-9.[30]FILIBERTI R, PARODI S, LIBENER R, et al.Diagnostic value of mesothelin in pleural fluids:comparison with CYFRA 21-1 and CEA[J].Medical Oncology, 2013, 30 (2) :1-9.
|
|
[31]
|
[31]MULEY T, DIENEMANN H, HERTH F J, et al.Combination of mesothelin and Csignificantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer[J].Journal of Thoracic Oncology Official Publication of the International Association for the Study of Lung Cancer, 2013, 8 (7) :947-951.[31]MULEY T, DIENEMANN H, HERTH F J, et al.Combination of mesothelin and Csignificantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer[J].Journal of Thoracic Oncology Official Publication of the International Association for the Study of Lung Cancer, 2013, 8 (7) :947-951.
|
|
[32]
|
[32]PASTAN I, HASSAN R.Discovery of mesothelin and exploiting it as a target for immunotherapy[J].Cancer Research, 2014, 74 (11) :2907-2912.[32]PASTAN I, HASSAN R.Discovery of mesothelin and exploiting it as a target for immunotherapy[J].Cancer Research, 2014, 74 (11) :2907-2912.
|
|
[33]
|
[33]ZHANG Y, XIANG L, HASSAN R, et al.Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2006, 12 (15) :4695-4701.[33]ZHANG Y, XIANG L, HASSAN R, et al.Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2006, 12 (15) :4695-4701.
|
|
[34]
|
[34]HASSAN R, SHARON E, SCHULER B, et al.Antitumor activity of SS1P with pemetrexed and cisplatin for front-line treatment of pleural mesothelioma and utility of serum mesothelin as a marker of tumor response.[J].Journal of Clinical Oncology, 2011, 29 (15) :2696-2696.[34]HASSAN R, SHARON E, SCHULER B, et al.Antitumor activity of SS1P with pemetrexed and cisplatin for front-line treatment of pleural mesothelioma and utility of serum mesothelin as a marker of tumor response.[J].Journal of Clinical Oncology, 2011, 29 (15) :2696-2696.
|
|
[35]
|
[35]HASSAN R, WILLIAMS-GOULD J, WATSON T, et al.Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1[J].Forensic Science International Genetics Supplement, 2004, 10 (1) :16-18.[35]HASSAN R, WILLIAMS-GOULD J, WATSON T, et al.Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1[J].Forensic Science International Genetics Supplement, 2004, 10 (1) :16-18.
|
|
[36]
|
[36]HASSAN R, MILLER A C, SHARON E, et al.Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression[J].Science Translational Medicine, 2013, 5 (208) :888-891.[36]HASSAN R, MILLER A C, SHARON E, et al.Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression[J].Science Translational Medicine, 2013, 5 (208) :888-891.
|
|
[37]
|
[37]ZHANG J, KHANNA S, JIANG Q, et al.Efficacy of anti-mesothelin immunotoxin RG7787 plus nab-paclitaxel against mesothelioma patient derived xenografts and mesothelin as a biomarker of tumor response[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2016, 23 (6) :1564-1574.[37]ZHANG J, KHANNA S, JIANG Q, et al.Efficacy of anti-mesothelin immunotoxin RG7787 plus nab-paclitaxel against mesothelioma patient derived xenografts and mesothelin as a biomarker of tumor response[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2016, 23 (6) :1564-1574.
|
|
[38]
|
[38]HASSAN R, EBEL W, ROUTHIER E L, et al.Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin[J].Cancer Immunity A Journal of the Academy of Cancer Immunology, 2006, 19 (7) :20-20.[38]HASSAN R, EBEL W, ROUTHIER E L, et al.Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin[J].Cancer Immunity A Journal of the Academy of Cancer Immunology, 2006, 19 (7) :20-20.
|
|
[39]
|
[39]HASSAN R, COHEN S J, PHILLIPS M, et al.Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers[J].Clinical Cancer Research, 2010, 16 (24) :6132-6138.[39]HASSAN R, COHEN S J, PHILLIPS M, et al.Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers[J].Clinical Cancer Research, 2010, 16 (24) :6132-6138.
|
|
[40]
|
[40] HASSAN R, KINDLER H L, JAHAN T, et al.Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2014, 20 (23) :5927-5936.[40]HASSAN R, KINDLER H L, JAHAN T, et al.Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2014, 20 (23) :5927-5936.
|
|
[41]
|
[41]HASSAN R, KINDLER H L, JAHAN T, et al.Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2014, 20 (23) :5927-5936.[41]HASSAN R, KINDLER H L, JAHAN T, et al.Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2014, 20 (23) :5927-5936.
|
|
[42]
|
[42]BENDELL J, BLUMENSCHEIN G, ZINNER R, et al.Abstract LB-291:First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC) , BAY 94-9343, in patients with advanced solid tumors[J].Cancer Research, 2013, 73 (8 Supplement) :291.[42]BENDELL J, BLUMENSCHEIN G, ZINNER R, et al.Abstract LB-291:First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC) , BAY 94-9343, in patients with advanced solid tumors[J].Cancer Research, 2013, 73 (8 Supplement) :291.
|
|
[43]
|
[43]BROCKER T, KARJALAINEN K.Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes[J].Journal of Experimental Medicine, 1995, 181 (5) :1653-1659.[43]BROCKER T, KARJALAINEN K.Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes[J].Journal of Experimental Medicine, 1995, 181 (5) :1653-1659.
|
|
[44]
|
[44]KERSHAW M H, WESTWOOD J A, PARKER L L, et al.A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2006, 12 (20 Pt 1) :6106-6115.[44]KERSHAW M H, WESTWOOD J A, PARKER L L, et al.A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2006, 12 (20 Pt 1) :6106-6115.
|
|
[45]
|
[45]LAMERS C H, WILLEMSEN R, VAN ELZAKKER P, et al.Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells[J].Blood, 2011, 117 (1) :72-82.[45]LAMERS C H, WILLEMSEN R, VAN ELZAKKER P, et al.Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells[J].Blood, 2011, 117 (1) :72-82.
|
|
[46]
|
[46]LE D T, BROCKSTEDT D G, NIR-PAZ R, et al.A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers:phase I studies of safety and immune induction[J].Clinical Cancer Research, 2012, 18 (3) :858-868.[46]LE D T, BROCKSTEDT D G, NIR-PAZ R, et al.A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers:phase I studies of safety and immune induction[J].Clinical Cancer Research, 2012, 18 (3) :858-868.
|
点击查看大图
下载:
